Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B

So Yeon Kim120 enrolled

Overview

The investigator aimed to prospectively study the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ATI value) in patients with chronic hepatitis B.

Chronic hepatitis B virus (HBV) infection has been reported to be associated with the prevalence of non-alcoholic fatty liver disease (NAFLD). Prior studies demonstrate that concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. Therefore, quantification of hepatic steatosis and fibrosis in chronic hepatitis B patient has important clinical significance in active surveillance. Ultrasound imaging provides reliable noninvasive quantification of hepatic steatosis and fibrosis. Attenuation imaging (ATI) reflects hepatic steatosis and 2D-shear wave elastography reflects hepatic fibrosis. The potential interaction between of the hepatic fibrosis and the hepatic steatosis in chronic hepatitis B is not fully understood. The investigator investigated the effect of the hepatic fibrosis on quantifying hepatic steatosis using ultrasound attenuation imaging (ATI value) in patients with chronic hepatitis B.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Hepatic Steatosis Hepatic Fibrosis Chronic Hepatitis b

Eligibility

Sex: ALLMin age: 18 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic hepatitis B patients * Who is scheduled for pathological exam such as liver biopsy or surgery, that can quantify hepatic steatosis and hepatic fibrosis * Who submitted informed consent Exclusion Criteria: * Who underwent liver transplantation or right hemihepatectomy * Huge hepatic mass or numerous cysts in right hepatic lobe, who is not eligible for measuring ultrasound attenuation imaging and Fibroscan * High bleeding risk patients

Locations (2)

Asan Medical Center

Seoul, Songpa-gu , 88, Olympic-ro 43-gil, South Korea

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Attenuation Coefficient (AC) value at liver parenchyma

decibel(dB)/cm/megahertz(MHz)

Time frame: During procedure

Pathological hepatic steatosis

Non-alcoholic Steatohepatitis(NASH) Clinical Research Network scoring system as follows: S0, \<5%; S1, 5%-33%; S2, 34%-66%; S3, ≥67%

Time frame: During procedure

Pathological hepatic fibrosis

Meta-analysis of histological data in viral hepatitis(METAVIR) scoring system as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis

Time frame: During procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.